<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893035</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC 2005 DA</org_study_id>
    <nct_id>NCT00893035</nct_id>
  </id_info>
  <brief_title>Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients</brief_title>
  <official_title>Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the prediction of late toxicity by the&#xD;
      radiation induced CD8 T-lymphocyte apoptosis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two cancer sites concerned by this trial are intermediate risk prostate cancer treated&#xD;
      with conformational radiotherapy with or without intensity modulation, and breast cancer&#xD;
      patients treated with adjuvant radiotherapy after breast conservative surgery for patients&#xD;
      aged under 60 years of age. The identification of 5% of patients at risk of severe toxicity&#xD;
      should allow to deliver high dose radiotherapy among 95% of patients with a lower risk of&#xD;
      severe late complications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">October 29, 2019</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Late complications</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">885</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Intermediate prognosis prostate cancer</arm_group_label>
    <description>Intermediate prognosis prostate cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Breast cancer</arm_group_label>
    <description>conservative treatment and age&lt;60 Boost irradiation and age&gt;60</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        patients treated in a cancer center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for prostate cancer patients:&#xD;
&#xD;
          -  localised prostate cancer, histologically proven&#xD;
&#xD;
          -  Absence of metastases (M0) : normal bone scintigraphy&#xD;
&#xD;
          -  Absence of radiological lymph node invasion (N0).&#xD;
&#xD;
          -  Clinical Stage : T ≥ T1c-T2a and &lt; T3b Or T1b or c with PSA ≤ 10 ng/ml . Or T1b or c&#xD;
             with Gleason ≥ 6&#xD;
&#xD;
          -  PSA &lt; 30 ng/ml.&#xD;
&#xD;
          -  Signs and symptoms according to NCI/CTC v3.0 &lt; grade 2&#xD;
&#xD;
          -  ECOG Performance status ≤ 1&#xD;
&#xD;
          -  Absence of hip prothesis&#xD;
&#xD;
          -  Absence de endopenian stent&#xD;
&#xD;
          -  Patient aged &gt; 18 and &lt; 80&#xD;
&#xD;
          -  Patient affiliated with social security&#xD;
&#xD;
          -  Written informed consent, dated and signed&#xD;
&#xD;
        Exclusion Criteria for prostate cancer patients:&#xD;
&#xD;
          -  Antecedents of invasive cancer (unless if treated more than 5 years ago without&#xD;
             evolution) except basocellular carcinoma&#xD;
&#xD;
          -  positive biopsy of seminal vesicle&#xD;
&#xD;
          -  PSA ≥ 30 ng/ml for two successive dosages&#xD;
&#xD;
          -  Previous pelvic irradiation&#xD;
&#xD;
          -  Previous radical prostatectomy for cancer&#xD;
&#xD;
          -  Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary&#xD;
             embolism, etc.) non stabilised or generalised sclerodermitis.&#xD;
&#xD;
          -  Patients known to be HIV seropositive (no specific test is necessary for defining&#xD;
             eligibility)&#xD;
&#xD;
          -  Known homozygote ATM (Ataxy telangiectasy) mutation&#xD;
&#xD;
          -  Impossibility for a correct follow up (for social family or geographical reasons)&#xD;
&#xD;
          -  Patients incapable of providing consent, protected majors, vulnerable persons&#xD;
&#xD;
          -  Patients participating in other clinical trials&#xD;
&#xD;
        Inclusion Criteria for breast cancer patients:&#xD;
&#xD;
          -  Breast Conservative surgery&#xD;
&#xD;
          -  Non metastatic, M0&#xD;
&#xD;
          -  negative surgical margins&#xD;
&#xD;
          -  T1, T2; negative sentinel lymph node N0, N1 or N2.&#xD;
&#xD;
          -  Signs and symptoms according to NCI/CTC v3.0 &lt; grade 2&#xD;
&#xD;
          -  Patient aged over 18 years and less than 60 or more than 60 with an indication for&#xD;
             boost irradiation.&#xD;
&#xD;
          -  Patient affiliated with social security&#xD;
&#xD;
          -  Written informed consent, dated and signed&#xD;
&#xD;
        Exclusion Criteria for breast cancer patients:&#xD;
&#xD;
          -  Metastatic patients&#xD;
&#xD;
          -  Bilateral breast cancer (concomitant or previous) except in situ&#xD;
&#xD;
          -  T4 or N3 or treated by mastectomy&#xD;
&#xD;
          -  Patients with chemotherapy or neoadjuvant hormonotherapy&#xD;
&#xD;
          -  Patients with a previous other cancer within the last 5 years EXCEPT basocellular&#xD;
             carcinoma of the skin or in situ cancer of the uterus.&#xD;
&#xD;
          -  Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary&#xD;
             embolism, etc.) non stabilised or generalised sclerodermia.&#xD;
&#xD;
          -  Pregnant or breast feeding women&#xD;
&#xD;
          -  Patients known to be HIV seropositive (no specific test is necessary for defining&#xD;
             eligibility)&#xD;
&#xD;
          -  Known homozygote ATM (Ataxy telangiectasy) mutation&#xD;
&#xD;
          -  Impossibility for a correct follow up (for social family or geographical reasons)&#xD;
&#xD;
          -  Patients incapable of providing consent, protected majors, vulnerable persons&#xD;
&#xD;
          -  Patients participating in other clinical trials&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Azria</last_name>
    <role>Principal Investigator</role>
    <affiliation>CRLC Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CRLC Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2009</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Late side effects</keyword>
  <keyword>Predictive assay</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

